ReviewTherapeutic advances in urology
Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?
Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Delphi consensus of specialist radiologists on imaging criteria for gadolinium contrast use and whole-body MRI in prostate cancer.Insights into imaging · 2026Article
- Article
- Multimodal urinary biomarker panel achieves superior prostate cancer detection accuracy and reduces unnecessary biopsies.Translational oncology · 2026Article
- Time-Resolved Förster Resonance Energy Transfer Nanoassay Based on CdTe Quantum Dots for Sensitive Detection of Prostate Cancer Antigen 3.ACS applied nano materials · 2025Article
- Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic.Journal of extracellular vesicles · 2025Review
- RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.International journal of molecular sciences · 2025Article
- Article
- Proteomics of prostate cancer serum and plasma using low and high throughput approaches.Clinical proteomics · 2024Article
- Review
- Prostate Region-Wise Imaging Biomarker Profiles for Risk Stratification and Biochemical Recurrence Prediction.Cancers · 2023Article
- Rats, Neuregulins and Radical Prostatectomy: A Conceptual Overview.Journal of clinical medicine · 2023Review
- Endocrine Disrupting Chemicals Influence Hub Genes Associated with Aggressive Prostate Cancer.International journal of molecular sciences · 2023Article
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models.Diagnostics (Basel, Switzerland) · 2022Article
- A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data.Cancers · 2022Article
- Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men.Disease markers · 2022Article
- Article
- Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization.International journal of molecular sciences · 2021Review
- Advancements in Biomarkers of Prostate Cancer: A Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several advancements have been made in recent years with regards to the detection and evaluation of prostate cancer (PCa). The low specificity of prostate specific antigen (PSA) has left much to be desired in a test, but a boom in novel biomarkers has made screening and surveillance more complicated. Several attempts at identifying a niche for these tests has helped somewhat, but much is still undetermined about the benefit that each test provides. In addition to laboratory tests, advancements in multiparametric magnetic resonance imaging (mpMRI) and PIRADSv.2 scoring have provided significant benefit to the evaluation of PCa. With the widespread use of prostate imaging, it is important to re-evaluate the impact of novel biomarkers in the context of furthering PCa screening and management. In this review, we aim to assess the influence mpMRI has on the role of nine different novel biomarkers in the detection and evaluation of PCa. We performed a review of current peer-reviewed literature to assess this question. Much data has been published on the role of these tests, allowing for their placement into one of three best-fit categories: tests for biopsy-naïve men (Prostate Health Index, Mi Prostate Score, 4K Score); tests for men with prior negative biopsies (ConfirmMDx, Progensa PCA3); and men on active surveillance (OncotypeDx, Prolaris, Decipher). Data on the role of these tests with the use of mpMRI have not been comprehensive and excludes several of the markers. More research is needed to determine the combined impact mpMRI and the novel biomarkers on the evaluation and management of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.